988049603	988049603	CD	B-NP	O
|	|	NNP	I-NP	O
SHH	SHH	NNP	I-NP	O
|	|	VBD	B-VP	O
93522524	93522524	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
9569896	9569896	CD	B-NP	O
|	|	CC	I-NP	O
2/7/2004	2/7/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
dizziness	dizziness	NN	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/7/2004	2/7/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/14/2004	8/14/2004	CD	B-NP	O
******	******	SYM	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
CORKILL	CORKILL	NNP	B-NP	O
,	,	,	O	O
MICKEY	MICKEY	NNP	B-NP	O
076-87-98-8	076-87-98-8	CD	I-NP	O
Rhamcastaleah	Rhamcastaleah	NNP	I-NP	O
Nono	Nono	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
9/10/04	9/10/04	CD	B-NP	O
AT	AT	NN	I-NP	O
06	06	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
HO	HO	NN	I-NP	O
evaluation	evaluation	NN	I-NP	O
WILL	WILL	MD	B-VP	O
D/C	D/C	NNP	B-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
DEWYSE	DEWYSE	NNP	B-NP	O
,	,	,	O	O
KENDALL	KENDALL	NNP	B-NP	O
J.	J.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
81	81	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
Starting	Start	VBG	B-VP	O
STAT	STAT	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	O
7/13	7/13	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
1/16/04	1/16/04	CD	B-NP	O
by	by	IN	B-PP	O
LAHUE	LAHUE	NN	B-NP	O
,	,	,	O	O
HENRY	HENRY	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
WARFARIN	WARFARIN	NNP	B-NP	O
&	&	CC	I-NP	O
ASPIRIN	ASPIRIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	B-ADJP	O
,	,	,	O	O
pt	pt	JJ	B-ADJP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
AMIODARONE	AMIODARONE	NN	I-NP	O
200	200	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
1/16/04	1/16/04	CD	B-NP	O
by	by	IN	B-PP	O
DYMENT	DYMENT	NNP	B-NP	O
,	,	,	O	O
ISAAC	ISAAC	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
WARFARIN	WARFARIN	NNP	B-NP	O
&	&	CC	I-NP	O
AMIODARONE	AMIODARONE	NNP	I-NP	O
HCL	HCL	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
DIGOXIN	DIGOXIN	NNP	B-NP	O
&	&	CC	I-NP	O
AMIODARONE	AMIODARONE	NNP	I-NP	O
HCL	HCL	NN	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	I-NP	O
pt	pt	NN	I-NP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
DIGOXIN	DIGOXIN	NN	I-NP	O
0.125	0.125	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
1/16/04	1/16/04	CD	B-NP	O
by	by	IN	B-PP	O
MURIE	MURIE	NN	B-NP	B-protein
,	,	,	O	O
ELLIOTT	ELLIOTT	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
AMIODARONE	AMIODARONE	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
45409761	45409761	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
DIGOXIN	DIGOXIN	NNP	B-NP	O
&	&	CC	I-NP	O
AMIODARONE	AMIODARONE	NNP	I-NP	O
HCL	HCL	NN	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	I-NP	O
pt	pt	NN	I-NP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	B-protein
COLACE	COLACE	NN	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
DOCUSATE	DOCUSATE	NNP	I-NP	I-protein
SODIUM	SODIUM	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
LASIX	LASIX	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
120	120	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
NPH	NPH	NNP	I-NP	I-protein
HUMULIN	HUMULIN	NNP	I-NP	I-protein
INSULIN	INSULIN	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
NPH	NPH	NNP	I-NP	O
HUMAN	HUMAN	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
47	47	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
REGULAR	REGULAR	NNP	I-NP	O
HUMAN	HUMAN	NNP	I-NP	O
Sliding	Sliding	NNP	I-NP	O
Scale	Scale	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
subcutaneously	subcutaneously	RB	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
SC	SC	NN	I-NP	B-protein
AC+HS	AC+HS	NN	I-NP	I-protein
If	If	IN	B-SBAR	I-protein
BS	BS	NNP	B-NP	I-protein
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
125	125	CD	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
125-150	125-150	CD	B-NP	O
,	,	,	O	O
then	then	RB	O	O
give	give	VB	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
151-200	151-200	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
201-250	201-250	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
251-300	251-300	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
301-350	301-350	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
351-400	351-400	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
and	and	CC	O	O
call	call	VB	B-VP	O
HO	HO	NN	B-NP	B-protein
Call	Call	NN	I-NP	I-protein
HO	HO	NN	I-NP	I-protein
if	if	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
400	400	CD	B-NP	O
MILK	MILK	NN	I-NP	O
OF	OF	IN	B-NP	O
MAGNESIA	MAGNESIA	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
MAGNESIUM	MAGNESIUM	NNP	I-NP	O
HYDROXIDE	HYDROXIDE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
30	30	CD	I-NP	O
MILLILITERS	MILLILITERS	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Constipation	Constipation	NNP	I-NP	O
COUMADIN	COUMADIN	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
2	2	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QPM	QPM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
NOW	NOW	NNP	I-NP	O
,	,	,	O	O
Within	Within	NNP	B-NP	O
Hour	Hour	NNP	I-NP	O
of	of	IN	B-PP	O
Pharmacy	Pharmacy	NNP	B-NP	O
Approval	Approval	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
7/13	7/13	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
No	No	NNP	I-NP	O
high	high	JJ	I-NP	O
Vitamin-K	Vitamin-K	NN	I-NP	O
containing	contain	VBG	B-VP	O
foods	food	NNS	B-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
1/16/04	1/16/04	CD	B-NP	O
by	by	IN	B-PP	O
PALEN	PALEN	NN	B-NP	B-protein
,	,	,	O	O
EVERETTE	EVERETTE	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
92582808	92582808	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
WARFARIN	WARFARIN	NNP	B-NP	O
&	&	CC	I-NP	O
ASPIRIN	ASPIRIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	B-ADJP	O
,	,	,	O	O
pt	pt	JJ	B-ADJP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
1/16/04	1/16/04	CD	B-NP	O
by	by	IN	B-PP	O
LOTERBAUER	LOTERBAUER	NN	B-NP	O
,	,	,	O	O
PORTER	PORTER	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
AMIODARONE	AMIODARONE	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
45409761	45409761	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
WARFARIN	WARFARIN	NNP	B-NP	O
&	&	CC	I-NP	O
AMIODARONE	AMIODARONE	NNP	I-NP	O
HCL	HCL	NN	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	I-NP	O
pt	pt	NN	I-NP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
6/2/04	6/2/04	CD	B-NP	O
by	by	IN	B-PP	O
ODONALD	ODONALD	NNP	B-NP	O
,	,	,	O	O
EMANUEL	EMANUEL	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NNP	B-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	I-NP	O
SIMVASTATIN	SIMVASTATIN	NN	I-NP	O
80	80	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QHS	QHS	NN	I-NP	O
Starting	Start	VBG	B-VP	O
STAT	STAT	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	O
10/24	10/24	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Override	Override	NNP	B-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
6/2/04	6/2/04	CD	B-NP	O
by	by	IN	B-PP	O
KIDWELL	KIDWELL	NNP	B-NP	O
,	,	,	O	O
RICHIE	RICHIE	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
COUMADIN	COUMADIN	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
24804635	24804635	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NNP	B-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MD	MD	NN	B-NP	O
aware	aware	JJ	I-NP	O
NORVASC	NORVASC	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
AMLODIPINE	AMLODIPINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
10	10	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
95	95	CD	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

IMDUR	IMDUR	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ISOSORBIDE	ISOSORBIDE	NNP	I-NP	O
MONONIT	MONONIT	NNP	I-NP	O
.	.	.	O	O

-LRB-	-LRB-	NN	B-NP	O
SR	SR	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
60	60	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Give	Give	NNP	I-NP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
empty	empty	JJ	I-NP	O
stomach	stomach	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
give	give	VBP	B-VP	O
1hr	1hr	NN	B-NP	O
before	before	IN	B-SBAR	O
or	or	CC	O	O
2hr	2hr	NN	B-NP	O
after	after	IN	B-SBAR	O
food	food	NN	B-NP	B-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
KCL	KCL	NNP	I-NP	I-protein
IMMEDIATE	IMMEDIATE	NNP	I-NP	I-protein
RELEASE	RELEASE	NNP	I-NP	I-protein
40	40	CD	I-NP	I-protein
MEQ	MEQ	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
potassium	potassium	NN	B-NP	O
>	>	SYM	B-NP	O
4.5	4.5	CD	B-NP	O
As	As	IN	B-ADJP	O
per	per	IN	B-PP	O
ICH	ICH	NN	B-NP	O
Potassium	Potassium	NN	I-NP	O
Chloride	Chloride	NN	I-NP	O
Policy	Policy	NN	I-NP	O
:	:	:	O	O
each	each	DT	B-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
with	with	IN	B-PP	O
4	4	CD	B-NP	O
oz	oz	NN	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	NN	B-NP	O
COZAAR	COZAAR	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
LOSARTAN	LOSARTAN	NN	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
100	100	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QHS	QHS	NN	I-NP	O
Starting	Start	VBG	B-VP	O
STAT	STAT	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	B-NP	O
10/24	10/24	CD	I-NP	O
-RRB-	-RRB-	SYM	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
95	95	CD	O	O
Number	Number	NNP	O	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
3	3	CD	B-NP	O
PLAVIX	PLAVIX	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
CLOPIDOGREL	CLOPIDOGREL	NN	I-NP	B-protein
-RRB-	-RRB-	HYPH	B-NP	O
75	75	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
Starting	Start	VBG	B-VP	O
STAT	STAT	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
7/13	7/13	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
NEXIUM	NEXIUM	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
ESOMEPRAZOLE	ESOMEPRAZOLE	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
20	20	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	I-protein
LEVOTHYROXINE	LEVOTHYROXINE	NNP	I-NP	I-protein
SODIUM	SODIUM	NNP	I-NP	I-protein
50	50	CD	I-NP	I-protein
MCG	MCG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
9/10/04	9/10/04	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
DIGOXIN	DIGOXIN	NNP	B-NP	O
&	&	CC	I-NP	O
LEVOTHYROXINE	LEVOTHYROXINE	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	B-NP	O
2	2	CD	I-NP	O
gm	gm	NN	I-NP	O
Na	Na	NN	I-NP	O
/	/	SYM	B-VP	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	I-NP	O
cals/day	cals/day	NN	I-NP	O
/	/	SYM	B-NP	O
Low	Low	NN	I-NP	O
saturated	saturate	VBD	B-VP	O
fat	fat	JJ	B-NP	O
low	low	JJ	I-NP	O
cholesterol	cholesterol	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Resume	Resume	VB	B-VP	O
regular	regular	JJ	B-NP	O
exercise	exercise	NN	I-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Kirkconnell	Kirkconnell	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
cardiology	cardiology	NN	I-NP	O
043-130-8469	043-130-8469	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
at	at	IN	B-PP	O
11	11	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
am	am	NN	I-NP	O
2/12/04	2/12/04	CD	B-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Mccaffrey	Mccaffrey	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
PCP	PCP	NN	I-NP	O
635-072-4095	635-072-4095	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
at	at	IN	B-PP	O
10	10	CD	B-NP	O
:	:	:	O	O
45	45	CD	B-NP	O
am	am	NN	I-NP	O
2/10/04	2/10/04	CD	B-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Ziebol	Ziebol	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
endocrinology	endocrinology	NN	I-NP	O
837-578-9683	837-578-9683	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
at	at	IN	B-PP	O
3	3	CD	B-NP	O
:	:	SYM	I-NP	O
00	00	CD	I-NP	O
pm	pm	NN	I-NP	O
10/11/04	10/11/04	CD	I-NP	O
,	,	,	O	O
Arrange	Arrange	NNP	B-NP	O
INR	INR	NNP	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
drawn	draw	VBN	I-VP	O
on	on	IN	B-PP	O
3/25/04	3/25/04	CD	B-NP	O
with	with	IN	B-PP	O
f/u	f/u	NN	B-NP	O
INR	INR	NNP	B-NP	O
's	's	POS	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
drawn	draw	VBN	I-VP	O
every	every	DT	B-NP	O
7	7	CD	I-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

INR	INR	NN	B-NP	O
's	's	POS	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Mac	Mac	NNP	I-NP	O
Strogen	Strogen	NNP	I-NP	O
ALLERGY	ALLERGY	NNP	I-NP	O
:	:	:	O	O
Cephalosporins	Cephalosporins	NNP	B-NP	O
,	,	,	O	O
ERYTHROMYCIN	ERYTHROMYCIN	NNP	B-NP	O
,	,	,	O	O
Penicillins	Penicillins	NNP	B-NP	O
ADMIT	ADMIT	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
dizziness	dizziness	NN	B-NP	O
,	,	,	O	O
ataxia	ataxia	NN	B-NP	O
PRINCIPAL	PRINCIPAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NN	B-NP	O
for	for	IN	B-PP	O
Causing	Cause	VBG	B-VP	O
Admission	Admission	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
dizziness	dizziness	NN	I-NP	O
OTHER	OTHER	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
s/p	s/p	VB	B-VP	O
right	right	JJ	B-NP	B-protein
CEA	CEA	NN	I-NP	I-protein
LBBB	LBBB	NN	I-NP	I-protein
on	on	IN	B-PP	O
EKG	EKG	NN	B-NP	O
hypertension	hypertension	NN	I-NP	O
diabetes	diabetes	NN	I-NP	O
EF	EF	NN	I-NP	O
25-30	25-30	CD	B-NP	O
%	%	NN	I-NP	O
CHF	CHF	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Ischemic	Ischemic	NNP	I-NP	O
Cardiomyopathy	Cardiomyopathy	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Atrial	Atrial	JJ	I-NP	O
Fibrillation	Fibrillation	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
symptomatic	symptomatic	JJ	B-NP	O
bradycardia	bradycardia	NN	I-NP	O
s/p	s/p	NN	I-NP	O
AICD/pacer	AICD/pacer	NN	I-NP	O
placement	placement	NN	I-NP	O
,	,	,	O	O
?	?	.	O	O

TIA	TIA	NN	B-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Chest	Chest	NNP	I-NP	O
PA	PA	NNP	I-NP	O
and	and	CC	O	O
Lateral	Lateral	JJ	B-ADJP	O
.	.	.	O	O

AICD	AICD	NNP	B-NP	O
Interrogation	Interrogation	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Kurt	Kurt	NNP	I-NP	O
Morring	Morring	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
BRIEF	BRIEF	NNP	I-NP	O
RESUME	RESUME	NNP	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
Ms	Ms	NNP	B-NP	O
Galabeas	Galabeas	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
71F	71F	NN	I-NP	O
with	with	IN	B-PP	O
DM	DM	NN	B-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	B-protein
,	,	,	O	O
s/p	s/p	NN	B-NP	O
3vCABG	3vCABG	NN	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
RCA	RCA	NN	I-NP	O
stent	stent	NN	I-NP	O
in	in	IN	B-PP	O
10/22	10/22	CD	B-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
-LRB-	-LRB-	SYM	I-NP	O
EF	EF	NN	I-NP	O
=	=	SYM	B-VP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
in	in	IN	B-PP	O
10/22	10/22	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
h/o	h/o	NN	B-NP	O
bradycardia	bradycardia	NN	I-NP	O
now	now	RB	B-ADVP	O
with	with	IN	B-PP	O
AICD/Pacer	AICD/Pacer	NN	B-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
R-CEA	R-CEA	NN	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
?	?	.	O	O

TIA	TIA	NN	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
dizziness	dizziness	NN	B-NP	O
,	,	,	O	O
ataxia	ataxia	NN	B-NP	O
x	x	SYM	B-NP	O
24H	24H	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
denies	deny	VBZ	B-VP	O
CP	CP	NN	B-NP	B-DNA
,	,	,	O	O
SOB	SOB	NN	B-NP	B-protein
,	,	,	O	O
palpitations	palpitation	NNS	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
denies	deny	VBZ	B-VP	O
melana	melana	NN	B-NP	O
;	;	:	O	O
BRBPR	BRBPR	NN	B-NP	B-protein
.	.	.	O	O

NO	NO	NN	B-NP	O
new	new	JJ	I-NP	O
meds	med	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
N/V/F	N/V/F	NN	I-NP	B-protein
/	/	SYM	B-NP	O
C	C	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
unlike	unlike	JJ	B-NP	O
anything	anything	NN	I-NP	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
,	,	,	O	O
labs	lab	NNS	B-NP	O
were	be	VBD	B-VP	O
all	all	DT	O	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

While	While	IN	B-SBAR	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
monitor	monitor	NN	I-NP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
bradycardia	bradycardia	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
40s	40	NNS	I-NP	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Hilmer	Hilmer	NNP	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
EP	EP	NN	I-NP	O
service	service	NN	I-NP	O
interogated	interogate	VBD	B-VP	O
the	the	DT	B-NP	O
device	device	NN	I-NP	O
and	and	CC	O	O
indicated	indicate	VBD	B-VP	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
working	work	VBG	I-VP	O
properly	properly	RB	B-ADVP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
arrhythmias	arrhythmia	NNS	I-NP	O
.	.	.	O	O

Telemetry	Telemetry	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NNP	I-NP	O
also	also	RB	B-ADVP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
record	record	VB	I-VP	O
the	the	DT	B-NP	O
bradycardic	bradycardic	JJ	I-NP	O
episode	episode	NN	I-NP	O
,	,	,	O	O
suggesting	suggest	VBG	B-VP	O
that	that	IN	B-SBAR	O
perhaps	perhaps	RB	B-ADVP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
an	an	DT	B-NP	O
artifact	artifact	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
's	's	POS	B-NP	O
toxicology	toxicology	NN	I-NP	O
screen	screen	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
vitals	vital	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	JJ	I-NP	B-cell_line
w	w	NN	I-NP	I-cell_line
ere	ere	NN	I-NP	I-cell_line
98.0	98.0	CD	I-NP	I-cell_line
,	,	,	I-NP	O
55	55	CD	I-NP	O
,	,	,	I-NP	O
176/60	176/60	CD	I-NP	O
,	,	,	I-NP	O
18	18	CD	I-NP	O
,	,	,	I-NP	O
98	98	CD	I-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dysmetria	dysmetria	NN	I-NP	O
;	;	:	O	O
no	no	DT	B-NP	O
dysdiadocokinesia	dysdiadocokinesia	NN	I-NP	O
;	;	:	O	O
negativ	negativ	NN	B-NP	O
e	e	NN	I-NP	O
Romberg	Romberg	NNP	B-NP	O
's	's	POS	B-NP	O
sign	sign	NN	I-NP	O
.	.	.	O	O

Hospital	Hospital	NNP	B-NP	O
Course	Course	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

CV	CV	NN	B-NP	O
:	:	:	O	O
pt	pt	NN	B-NP	O
ruled	rule	VBD	B-VP	O
out	out	RP	B-PRT	O
for	for	IN	B-PP	O
MI	MI	NN	B-NP	O
;	;	:	O	O
24H	24H	NN	B-NP	O
telemetry	telemetry	NN	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
arrhythmias	arrhythmia	NNS	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	B-protein
's	's	POS	B-NP	I-protein
BB	BB	NN	I-NP	I-protein
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
worry	worry	NN	B-NP	O
about	about	IN	B-PP	O
bradyarrhythmia	bradyarrhythmia	NN	B-NP	O
,	,	,	O	O
hypotension	hypotension	NN	B-NP	O
.	.	.	O	O

Continued	Continue	VBN	B-NP	O
antihypertensive	antihypertensive	JJ	I-NP	O
and	and	CC	I-NP	O
CAD	CAD	NN	I-NP	O
treatment	treatment	NN	I-NP	O
with	with	IN	B-PP	O
with	with	IN	B-PP	O
Cozaar	Cozaar	NNP	B-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
,	,	,	O	O
Isosorbide	Isosorbide	NNP	B-NP	O
,	,	,	O	O
Digoxin	Digoxin	NNP	B-NP	O
,	,	,	O	O
Amiodarone	Amiodarone	NNP	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
is	be	VBZ	B-VP	O
also	also	RB	B-ADVP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
,	,	,	O	O
Plavix	Plavix	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
ASA	ASA	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
was	be	VBD	B-VP	O
discussed	discuss	VBN	I-VP	O
w	w	NN	B-NP	O
/	/	SYM	O	O
pt	pt	NN	B-NP	O
's	's	POS	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Kallio	Kallio	NNP	I-NP	O
who	who	WP	B-NP	O
indicated	indicate	VBD	B-VP	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
a	a	DT	B-NP	O
new	new	JJ	I-NP	O
complaint	complaint	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
non-compliant	non-compliant	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

PT	PT	NN	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
Coreg	Coreg	NN	B-NP	O
but	but	CC	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
admit	admit	VB	I-VP	O
for	for	IN	B-PP	O
low	low	JJ	B-NP	O
BP	BP	NN	I-NP	O
's	's	POS	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
was	be	VBD	B-VP	O
hypertensive	hypertensive	JJ	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-VP	O
SB	SB	NN	B-NP	O
P	P	NN	I-NP	O
150	150	CD	B-NP	O
's	's	POS	B-NP	O
while	while	IN	B-SBAR	O
inpt	inpt	NN	B-NP	O
but	but	CC	O	O
we	we	PRP	B-NP	O
will	will	MD	B-VP	O
d/c	d/c	VB	I-VP	O
pt	pt	NN	B-NP	O
off	off	IN	B-PP	O
Coreg	Coreg	NNP	B-NP	O
and	and	CC	O	O
defer	defer	VB	B-VP	O
to	to	TO	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Doniel	Doniel	NNP	I-NP	O
for	for	IN	B-PP	O
reinstitution	reinstitution	NN	B-NP	O
of	of	IN	B-PP	O
beta	beta	SYM	O	O
blockade	blockade	NN	B-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

NEURO	NEURO	NN	B-NP	B-protein
:	:	:	O	O
pt	pt	NN	B-NP	O
's	's	POS	B-NP	O
neuro	neuro	NN	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
focal	focal	JJ	I-NP	O
signs	sign	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
cerebellar	cerebellar	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O
given	give	VBN	B-PP	O
her	her	PRP	B-NP	O
significant	significant	JJ	I-NP	O
vascular	vascular	JJ	I-NP	B-protein
risk	risk	NN	I-NP	I-protein
factors	factor	NNS	I-NP	I-protein
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
concern	concern	NN	B-NP	O
for	for	IN	B-PP	O
vertebral-basilar	vertebral-basilar	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

MRI/MRA	MRI/MRA	NN	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
possible	possible	JJ	B-ADJP	O
given	give	VBN	B-NP	O
pt	pt	NN	I-NP	O
's	's	POS	B-NP	O
AICD/pacer	AICD/pacer	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
discussion	discussion	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-VP	O
team	team	NN	B-NP	O
CT/CTA	CT/CTA	NN	I-NP	O
were	be	VBD	B-VP	O
deferred	defer	VBN	I-VP	O
given	give	VBN	B-PP	O
pt	pt	NN	B-NP	O
's	's	POS	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
and	and	CC	I-NP	O
risk	risk	NN	I-NP	O
of	of	IN	B-PP	O
contrast	contrast	NN	B-NP	O
nephropathy	nephropathy	NN	I-NP	O
coupled	couple	VBN	B-VP	O
with	with	IN	B-PP	O
our	our	PRP$	B-NP	O
feeling	feeling	NN	I-NP	O
that	that	IN	B-SBAR	O
any	any	DT	B-NP	O
findings	finding	NNS	I-NP	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
change	change	VB	I-VP	O
pt	pt	JJ	B-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discussed	discuss	VBN	I-VP	O
with	with	IN	B-PP	O
pt	pt	NN	B-NP	O
's	's	POS	B-NP	O
PCP	PCP	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Benedict	Benedict	NNP	I-NP	O
Wichern	Wichern	NNP	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

ENDO	ENDO	NN	B-NP	B-protein
:	:	:	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
home	home	NN	B-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
with	with	IN	B-PP	O
coverage	coverage	NN	B-NP	O
with	with	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
have	have	VBP	B-VP	O
a	a	DT	B-NP	O
TSH	TSH	NN	I-NP	O
of	of	IN	B-PP	O
158	158	CD	B-NP	O
FT4	FT4	NN	I-NP	O
1.8	1.8	CD	B-NP	O
,	,	,	O	O
FT3	FT3	NN	B-NP	O
56	56	CD	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
discussion	discussion	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
pt	pt	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
revealed	reveal	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
previously	previously	RB	I-VP	O
been	be	VBN	I-VP	O
diagnosed	diagnose	VBN	I-VP	O
and	and	CC	O	O
begun	begin	VBN	B-VP	O
on	on	IN	B-PP	O
replacement	replacement	NN	B-NP	O
but	but	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
know	know	VB	I-VP	O
what	what	WP	B-NP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
for	for	IN	B-PP	O
and	and	CC	O	O
subsequently	subsequently	RB	B-VP	O
stopped	stop	VBD	I-VP	O
it	it	PRP	B-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
own	own	JJ	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
started	start	VBD	B-VP	O
on	on	IN	B-PP	O
synthroid	synthroid	NN	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
f/u	f/u	JJ	B-NP	O
w/endocrine	w/endocrine	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
the	the	DT	B-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
Nexium	Nexium	NN	B-NP	O
;	;	:	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
already	already	RB	I-VP	O
anticoagulated	anticoagulate	VBN	I-VP	O
with	with	IN	B-PP	O
ASA	ASA	NN	B-NP	O
,	,	,	I-NP	O
plavix	plavix	NN	I-NP	O
and	and	CC	I-NP	O
Coumadin	Coumadin	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Disp	Disp	NN	B-NP	O
:	:	:	O	O
Pt	Pt	NN	B-NP	O
to	to	TO	B-PP	O
follow-up	follow-up	JJ	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-VP	O
Dr.	Dr.	NN	B-NP	O
Kishaba	Kishaba	NN	I-NP	O
for	for	IN	B-PP	O
managment	managment	NN	B-NP	O
of	of	IN	B-PP	O
CHF/BP	CHF/BP	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Blagg	Blagg	NNP	I-NP	O
for	for	IN	B-PP	O
f/u	f/u	NN	B-NP	O
of	of	IN	B-PP	O
potential	potential	JJ	B-NP	O
neurovascular	neurovascular	JJ	I-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
symptoms	symptom	NNS	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
to	to	TO	B-VP	O
f/u	f/u	VB	I-VP	O
with	with	IN	B-PP	O
endocrinology	endocrinology	NN	B-NP	O
for	for	IN	B-PP	O
managment	managment	NN	B-NP	O
of	of	IN	B-PP	O
hypothyroidism	hypothyroidism	NN	B-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

continue	continue	JJ	B-NP	O
levothyroxine	levothyroxine	NN	I-NP	O
for	for	IN	B-PP	O
hypothyroidism	hypothyroidism	NN	B-NP	O
.	.	.	O	O

f/u	f/u	NN	B-NP	O
endo	endo	NN	I-NP	O
for	for	IN	B-PP	O
management	management	NN	B-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

f/u	f/u	SYM	O	O
w	w	NN	B-NP	O
/	/	SYM	O	O
Dr.	Dr.	NNP	B-NP	O
Schryer	Schryer	NNP	I-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
reinstitution	reinstitution	NN	I-NP	O
of	of	IN	B-PP	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
and	and	CC	I-NP	O
CHF/BP	CHF/BP	NN	I-NP	B-protein
management	management	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

f/u	f/u	NN	B-NP	O
Dr.	Dr.	NNP	I-NP	O
Hackborn	Hackborn	NNP	I-NP	O
for	for	IN	B-PP	O
w/u	w/u	NN	B-NP	O
potential	potential	JJ	I-NP	O
vertebral-basilar	vertebral-basilar	JJ	I-NP	O
insufficieny	insufficieny	NN	I-NP	O
with	with	IN	B-PP	O
recognition	recognition	NN	B-NP	O
of	of	IN	B-PP	O
risk	risk	NN	B-NP	O
of	of	IN	B-PP	O
iv	iv	NN	B-NP	O
contrast	contrast	NN	I-NP	O
nephropathy	nephropathy	NN	I-NP	O
vs	vs	IN	B-PP	O
utility	utility	NN	B-NP	O
of	of	IN	B-PP	O
information	information	NN	B-NP	O
No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
CRAMM	CRAMM	NNP	B-NP	O
,	,	,	O	O
ALAN	ALAN	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
LW26	LW26	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
9/10/04	9/10/04	CD	I-NP	O
@	@	NN	I-NP	O
06	06	CD	I-NP	O
:	:	:	O	O
12	12	CD	B-NP	O
PM	PM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

